NURS FPX 9010 Assessment 2 Project Proposal

Student name

Capella University

NURS-FPX9010

Professor Name

Submission Date

Project Proposal

The increasing rates of poorly controlled Type 2 diabetic patients in the practice site have identified the ongoing issues concerning non-compliant insulin adherence, inappropriate self-management habits, and the lack of understanding of daily insulin administration patterns that have direct effects on glycemic control. Despite nursing personnel offering routine diabetes education and medication counseling when the nurses encounter patients clinically, the scope of these sessions is short and intermittent; therefore, the outcomes of this intervention have not yielded long-lasting benefit in glycemic control.

It was shown that ADA-conformant interventions in diabetes technologies, especially those that incorporate FDA-approved smart insulin pens with dose-logging and missed-dose alert functions into systematic, nurse-in-charge clinical management plans, enhance insulin adherence, increase medication safety, and promote meaningful changes in HbA1c (Galindo et al., 2021).

The Standards of Care in Diabetes offered by the American Diabetes Association (ADA) include the application of insulin delivery technologies, which are integrated into standardized clinical patterns and team-based care frameworks to maximize glycemic control and interaction with the patient.

The PICOT question to be used by the project is: Among nurses working with adults having diabetes, on the usage of insulin (P), implementing an ADA-oriented smart insulin pen clinical management toolkit (I), versus current practices (C), how does the implementation of the tool reduce patient HbA1c values (O) within 12 weeks (T)? The subsequent proposal is a detailed proposal to implement and test an ADA-compliant Smart Insulin Pen Clinical Management Toolkit in the practice location to enhance nursing workflow, standardize insulin management practices, and patient glycemic outcomes.

Practice Problem

The emergence of diabetes type 2 diabetes is a major issue in outpatient primary care clinics. The clinic has a culturally diverse population that is estimated to serve approximately 5,000 adult patients each year, with almost 40 percent of them being classified as a high-risk group for Type 2 diabetes. The patient outcome reviews of the recent history have shown that emergency visits in relation to hyperglycemia are common (Nurse Manager, personal communication, October 10, 2025).

In the project site, the adult patients with type 2 diabetes have poor self-management practices and adherence, which is one of the factors contributing to high fasting glucose levels of 145 mg/dL, which could be described as poor glycemic control. As per the American Diabetes Association (2023), the normal level of fasting glucose is less than 100 mg/dL; hence, the current site average of 145mg/dL suggests a suboptimal self-management behavior, which results in poor glycemic control that falls short of the established standards.

Over the last six months, the clinic has been handling a patient population of about 450 adults with Type 2 diabetes whose average fasting glucose levels stand at about 145mg/dl, which is significantly higher than the recommended value of less than 100mg/dl by the ADA (Executive nurse, personal communication, October 10, 2025). A chronic high count of patients in such a large number indicates poor glycemic control and further proves that there is a need to enhance diabetes management levels in the location. The nursing staff is likely to enhance the implementation of the ADA-aligned Smart Insulin Pen Clinical Management Toolkit, which would alleviate insulin adherence and self-management behaviors leading to reduced HbA1c levels and the overall glycemic control in 12 weeks.

Impact on Individuals and Stakeholders

Poor self-management of diabetes has spillover effects to various areas of patient welfare, in addition to the fact that poor screening of persons at risk has added to the problem of late diagnosis and treatment. Lamptey et al. (2022) stated that lower outcomes that were caused by poor self-management were directly correlated, and structured DSME improved glycemic control. To healthcare employees and managers, the resulting issue of the evidence-based model being inconsistently implemented results in internal workflow inefficiencies and poor performance indicators on several critical quality domains.

Asmat et al. (2024) found that glycemic control is greatly enhanced with the help of patient-centered self-management interventions. Nevertheless, there is still a gap between the current practices in the project site, which are not informed by evidence-based practices that have proven effective in transforming patient outcomes. The existing measures of the clinic indicate that it is necessary to engage in regular use of an evidence-based model to enhance self-management practices, resulting in better glycemic control.

Recognizing Potential Areas for Improvement or Additional Knowledge

The existing interventions at the location should be improved to better support self-management practices among patients with Type 2 diabetes. The strategies need to be incorporated into the current workflow by training the staff and conducting regular compliance reviews. Further studies are needed on how protocol-based diabetes management is sustainable in the long run (Lamptey et al., 2022). The compliance with the principles of CITI in the project supports ethical data management, patient confidentiality, and compliance with the institutional quality improvement norms.

The enhancement of the aspects will boost the implementation fidelity and result in the self-management outcomes of adult patients with Type 2 diabetes. The practice issue is a symptom of an inefficient process that is based on inconsistent technology-facilitated insulin management, the absence of regularized nurse follow-up, and inconsistency in the nursing documentation regarding insulin administration and adherence measurement.

The problem was identified as a result of EHR audits, communication with the executive nurse, and trend analysis that showed the chronically high levels of HbA1c during six months of clinical care. The identified concern is supported by national data. According to the Centers for Disease Control and Prevention (2024), over 37 million Americans have diabetes, and almost half of them cannot meet the recommended glycemic levels, often because these people do not monitor insulin adherence and do not use diabetes management technologies.

In the same vein, the American Diabetes Association (2023) demonstrated a critical lack of integration of FDA-approved technologies in insulin delivery into normal outpatient care. The gap indicates a considerable necessity for organization, nurse-based clinical control models that will encompass the use of smart insulin pens to aid adherence measurement, enhance glycemic profiles, and minimize diabetes related complications and hospitalizations.

Project Site

The location of the project is an outpatient-based primary care clinic within a suburban area of New Jersey. The clinic falls under a community-based health network where the clinic focuses on accessible and patient-focused care among adults and the older population. Examples of services are regular check-ups, check-up education, and laboratory tests. The facility has a team-based care model that incorporates medical, nursing, and administrative staff so as to facilitate continuity of care. The clinic has an average of 15-20 patients per week, and about 40% of them treat Type 2 diabetes or various metabolic diseases (Executive nurse, personal communication, October 10, 2025).

The facility has three well-furnished examination rooms, a small laboratory with point-of-care testing, and a patient education room where counselling of patients can be carried out. The interprofessional team comprises a physician, nurse practitioners, registered nurses, a medical assistant, and a part-time diabetes educator. The introduction of electronic health records (EHR) in the clinic facilitates the use of data to make decisions and a continuous quality improvement (QI) effort.

Potential Implications of the Project Site for the Project

An ideal setting for the application of an evidence-based model is the primary care setting. The fact that the clinic focuses on prevention and the management of chronic diseases has a strong connection with the objectives of the project that aim at enhancing the fasting glucose levels of adults living with Type 2 diabetes. This is the benefit of the nurse-led practice model, as it takes advantage of the expertise of nurses, which is paramount in diabetes management (Baek et al., 2023). The lack of budget can, nevertheless, be a barrier to accessing the sophisticated diagnostic tools, so the resources available should be used effectively.

The nurse-led strategy enables cost-effective implementation and improves self-management behaviors. The specified project is consistent with the mission of the organization to provide patients with accessible and patient-centered chronic disease care and reinforces the available quality improvement programs. Past quality improvement initiatives at the site were based on medication adherence and lifestyle counseling, but did not have a standardized, technology-enabled insulin management model and thus did little to sustainably improve glycemic outcomes. The project will indirectly address the strategic efforts of the clinic, as the proposed ADA-consistent Smart Insulin Pen Clinical Management Toolkit will help the clinic to achieve its performance goals related to population health, the ability to achieve diabetes-specific quality indicators, and minimize unnecessary use of the emergency department.

Project Population

The population of the project is the adult type 2 patients aged 18 years and above who have been diagnosed with diabetes and are currently receiving care in the outpatient primary care clinic and are under insulin medication. This group of people has some common features, such as the burden of chronic diseases, a wide range of cultural backgrounds, and different degrees of insulin self-management skills. The following criteria will be used to include the project population: (a) a diagnosed Type 2 diabetes, (b) insulin therapy, (c) active, and (d) at least one clinic visit over the last six months, and (d) HbA1c data included in the electronic health record.

The population who will be excluded will consist of Type 1 diabetic patients, gestational diabetic patients, patients with severe cognitive impairment, or patients incapable of obtaining and/or being a participant in smart insulin pen-supported care processes. To identify clinically significant shifts in the HbA1c in the12-week period of intervention, a minimum of 30-50 patients will be needed. The available population can be used in the context of quality improvement, as there are over 450 adult patients with Type 2 diabetes under the care of the clinic during the last six months, which is enough to aid in the recruitment process and provide the continuity of data used to evaluate performance changes.

Evidence-Based Interventions

Necessary intervention should be based on evidence to enhance insulin adherence and glycemic control in adults with Type 2 diabetes undergoing an insulin regimen. The main intervention of the project in question is a Smart Insulin Pen Clinical Management Toolkit based on the principles of ADA that incorporates the use of FDA-approved smart insulin pens with dose-logging functionalities and missed-dose alarms into the daily nursing practices. The intervention also changes the pattern of diabetes management based on education-only methods to an approach that is data-informed, technology-empowered insulin monitoring, putting nurses in a position to proactively detect missed doses, assess the pattern of injection, and intervene in real time to promote the best glycemic regulation.

The usefulness of the smart insulin pen technology in enhancing adherence and glycemic control was supported by evidence. Galindo et al. (2021) proved that there was a statistically significant difference in the reduction of HbA1c and the number of missed insulin doses in adults with uncontrolled Type 2 diabetes who used a smart insulin pen cap compared to ordinary pen use in a randomized crossover study. Equally, a large multinational retrospective study by Danne et al. (2024) revealed that both missed basal and bolus insulin injections and adherence to using smart insulin pens were strongly associated with highly glycemic results and better HbA1c and time-in-range values, respectively. Dose-logging and missed-dose alerts are some of the mechanisms that enhance insulin compliance and glycemic control.

The findings are supported by other real-world and cohort studies. According to Pantanetti et al., adults with standard insulin injections who switched to a smart pen-based system of insulin delivery showed significant differences in the mean glucose level, time-in-range, and the number of cases of hyperglycemia (Pantanetti et al., 2025). Equally, a 2025 study in Diabetes Research and Clinical Practice was able to show greater adherence and a significant reduction in HbA1c in adults using connected reversible insulin pens over those using conventional insulin pens (Chico et al., 2025). An organized introduction of smart insulin pen technology can help to improve glycemic control by decreasing the number of misses and helping to maintain the regularity of insulin introduction.

The national clinical guidelines support the implementation of the Smart Insulin Pen Clinical Management Toolkit. The Standards of care in Diabetes Technology Section of the American Diabetes Association encourages the use of connected insulin pens among patients under insulin treatment to enhance adherence and improve medication safety, and improve HbA1c reduction provided as part of structured care models (ElSayed et al., 2024). ADA recommendations suggest that the optimal way to use technology-based insulin management involves its integration into regular clinical processes and care models, such as nurse-led follow-up and monitoring guidelines.

Implementation plan for Interventions

Step-by-Step Process for Implementing the Intervention

The Smart Insulin Pen Clinical Management Toolkit will be implemented through a process with a systematic and serial flow that ensures the fidelity, consistency, and replicability throughout the clinical setting. The first stage will be the staff training program, where nurses and nurse practitioners, medical assistants, and the diabetes educator are thoroughly trained on the smart insulin pen system, the ADA technology guidelines, and workflow integration and standardized EHR documentation process (ElSayed et al., 2024; ADA, 2025).

The initial stage makes sure that all members of the staff are familiar with operational procedures and clinical guidelines related to the intervention, and this is an important step in the implementation fidelity (Chico et al., 2025). T2DM patients under insulin therapy that is prescribed to eligible adults will be recognized by weekly electronic health record (EHR) reports with diagnosis codes and recent fasting glucose/HbA1c values. The report will be generated by medical assistants, and the project lead will check the eligibility in relation to preset inclusion and exclusion criteria.

Patients will be enrolled and onboarded individually after enrollment with smart insulin pens, such as device set-up, dose-logging education, and being taught how to respond to missing-dose notifications. Nurses will examine the insulin administration data weekly, give feedback, and assist with the changes in dosing schedules or self-management practices. HbA1c and glucose data will be evaluated monthly to assess compliance, determine trends, and apply changes to the care delivery process iteratively.

It has been shown that well-organized smart insulin pen interventions that involve nurses yield better adherence and HbA1c results and assist in maintaining glycemic control (Galindo et al., 2021; Danne et al., 2024; Pantanetti et al., 2025). All interactions with patients, insulin dose information, missed dose notifications, and adherence evaluation will be recorded in a standardized EHR template. Frequent review meetings and stakeholder huddles will evaluate adherence to workflows, determine obstacles to processes, and make changes to strategies through formative data, and clinical processes and patient outcomes will continue to be optimized.

Learner Role and Scholarly Leadership

The learner, as the head of the scholarly project, is going to control all the operations and clinical aspects of the Smart Insulin Pen Clinical Management Toolkit intervention to maintain evidence-based standards and correspondence with the project goals. The learner will organize personnel training on the use of the smart insulin pen, competency checks in the setup and review of data, guarantee that the patient identification processes are performed in a consistent fashion, and the insulin dose monitoring and missed-dose alert processes are applied in accordance with standardized procedures. The other duties involve ethical control, which is in tandem with the CITI training, checking the accuracy of documentation, data integrity, and a weekly review of workflow compliance.

It has been demonstrated that effective project leadership, which is active supervision, verifying competencies, and regular monitoring, has a significant positive impact on fidelity to evidence-based interventions and elevates the efficacy of technology-based insulin management interventions (Ernawati et al., 2021). The learner will also review staff feedback, monitor new challenges, and preside over the ongoing quality checks to contribute to procedural fidelity. The proactive leadership approach, effective communication, and systematic supervision enable the learner to ensure that all the steps of the project are followed accurately and that the data is based on the correct clinical processes related to the use of a smart insulin pen.

Preceptor Partnership and Oversight Support

The evaluation plan will be aimed at determining how effective the ADA-aligned Smart Insulin Pen Clinical Management Toolkit is in enhancing insulin adherence and glycemic control in adults with Type 2 diabetes. HbA1c is the main outcome metric, and its fluctuations are to be monitored during the 12-week intervention timeframe based on the standard laboratory results that should be recorded in the EHR. The secondary outcome measures will be the number of missed insulin doses, dose-logging adherence frequency, and time-in-range measures based on the information reported by smart pens. Monitoring and follow-up documentation that will be led by nurses will offer measures of processes, such as compliance with workflow procedures by the staff, correctness of dose review, and prompt reaction to alerts on missed doses. The insulin adherence measures will be collected every week, and HbA1c will be collected every month, which will make it possible to recognize early changes and make changes through trial and error.

All the interactions with patients, smart pen information, and adherence feedback will be recorded using standardized EHR templates. The compliance among staff, workflow issues, and intervention fidelity will be evaluated during formative evaluation meetings and assessed according to ADA Standards of Care of diabetes technology (ElSayed et al., 2024). The anticipated results are statistically and clinically significant changes in the HbA1c level after 12 weeks, the frequency of insulin administration errors, patient compliance with insulin administration, and nurse follow-up and monitoring compliance.

It has been shown that properly organized adherence to smart insulin pens with dose-sensing and missed-dose alert capabilities can enhance glycemic variation, reduce glycemic control, and maintain glycemic control sustainability (Galindo et al., 2021; Danne et al., 2024; Pantanetti et al., 2025; Chico et al., 2025). The use of process evaluation will also involve the determination of competency and workflow integration of the staff, and will involve making sure that the nurses are always using standardized protocols that concern dose review, patient education, and missed-dose follow-up. The expected positive results in these areas will enable further implementation of smart insulin pen-based management as a new benchmark in the clinic, and this will serve as an exemplary foundation for enhancing the glycemic outcomes of patients with Type 2 diabetes.

Stakeholder Engagement and Participation

The stakeholder involvement is a significant determinant of the success of the smart insulin pen clinical management toolkit intervention. The internal stakeholders consist of nurses, nurse practitioners, physicians, medical assistants, the diabetes educator, clinic administrators, and quality improvement personnel. Expert individuals will be engaged through patient onboarding to smart insulin pens, patient identification, dose schedule organization, dose and adherence data, missed dose notifications, and administrative logistics.

New workflows, involvement in training, and standardized documentation processes will be imposed on internal stakeholders, and they will directly feel the impact through changes in the structure of visits, more focus on the use of technology to manage insulin, and more tasks with dose review and follow-up. Proactive participation of internal stakeholders in organized, technology-based insulin programs has been demonstrated to raise the fidelity of the implementation, the commitment of the staff to the standardized practices, and the patient-focused outcomes of chronic disease management (Silva et al., 2022).

Adult patients using smart insulin pens, family members engaged in insulin self-management support, and community-based partners to supplement larger diabetes resources are all external stakeholders. Changes in communication approaches, the education on the use of devices, and access to the structured adherence support strategies will impact identified stakeholders, and engagement and satisfaction will become the primary measures to indicate the acceptability and sustainability of the intervention. Involving external stakeholders (patients, families, and community partners) in technology-based insulin management initiatives has been linked to increased adherence, increased satisfaction, and better sustainability of intervention outcomes (Ernawati et al., 2021; Asmat et al., 2024). As part of the evaluation plan, patient satisfaction and perceived usefulness of the smart insulin pen toolkit will be followed.

Interprofessional Team Roles and Responsibilities

The interprofessional team that is being provided by the smart insulin pen clinical management toolkit intervention presents a well- outlined variety of roles to implement it efficiently and in a well-organized manner. The registered nurses shall onboard the patients into smart insulin pens, examine dose-logging information, answer missed-dose notifications, offer adherence counseling, and document every interaction with the use of standardized EHR templates.

The clinical oversight will be conducted by nurse practitioners and physicians who will ensure that there is a match between the smart pen data interpretation and the personalized treatment plans, and will also deal with medical concerns that are identified with the use of dose monitoring. Medical assistants will take care of the EHR-based patient identification, arranging smart pen onboarding and follow-up, adherence tracking, and cooperating with data collection processes. Technology-enabled insulin management programs, including external stakeholders such as patients, families, and community partners, have been linked to enhancing adherence, increased satisfaction, and increased sustainability of intervention results (Ricci et al., 2023).

The complex cases will be specifically counseled by the diabetes educator, and the nursing staff will be assisted in encouraging the patients to use smart pens. The quality improvement coordinator shall help in managing the data, ensuring that the data used to measure the outcomes are reliable, and also by keeping track of the compliance of the improvement process. The clinic administrator will make sure of the access to resources, logistics of scheduling, communication systems, and workflow modification.

The implementation of interprofessional roles, like diabetes educators, quality improvement coordinators, and administrators, proved to increase the effectiveness of the program, patient outcomes, and the adherence rate to the evidence-based technology-enabled diabetes management protocols (Ernawati et al., 2021). The project will also be coordinated by involving the interprofessional team in well-defined tasks, reducing redundancy, and including collective expertise that is required to bring the desired change in insulin adherence and glycemic results.

Data Collection, Analysis, and Desirable Outcomes

Desired Outcomes

The project outcomes desired are improvements in the level of insulin adherence and glycemic control among adult patients with Type 2 diabetes. The main project outcome is expected to change poor glycemic regulation (done by the decrease in the mean HbA1c and fasting glucose levels to ADA level (<130 mg/dL fasting glucose) in 12 weeks of applying the smart insulin pen clinical management toolkit by increasing adherence to insulin regimens prescribed to patients. Secondary outcomes consist of patient engagement with insulin administration, fewer insulin doses missed, and unnecessary referrals to specialist services. Insulin adherence and dose logging data will be monitored weekly using EHR, where adherence trends can be analyzed and compliance of the staff across the smart pen monitoring processes. Before and after intervention measures will give objective data about goal achievements.

The ADA-aligned smart insulin pen intervention effectiveness in the practice site will be directly measured by means of selected toolkit measures. The quantitative measures will be the mean HbA1c, fasting glucose, the rate of missing doses, documentation compliance levels, and the baseline and 12-week outcomes. Qualitative indicators will consist of nursing personnel feedback, the survey of patient satisfaction, and measuring the viability, usability, and sustainability of the intervention (Ricci et al., 2023). Taken together, these measures will provide evidence of the project’s success in enabling insulin management, which is evidence-based and supported by technologies, and enhance the quality of diabetes care.

Measurement of Outcomes

The point-of-care fasting blood glucose level will be used to measure clinical outcomes (at baseline (within 2 weeks before the beginning of the intervention) and monthly subsequently), with special emphasis put on the 12-week value, which will be the primary post-intervention outcome. The availability of secondary clinical evidence will involve HbA1c values (when ordered within the 3-month time frame of the intervention period), but fasting glucose is the main operational outcome since it is usually available in the clinic. Adherence to insulin and frequency of missed doses will also be monitored weekly using smart insulin pen dose-logging data.

Validated measures, including a summary of diabetes self-care activities (SDSCA) to determine the behaviors of adherence (glucose monitoring, injection consistency, medication adherence) and the diabetes self-efficacy scale to reflect the perceived ability to manage insulin therapy, will be used to measure self-management behaviors and self-efficacy at baseline and at 12 weeks.

Adherence behaviors and perceived competency have been effectively measured using validated instruments like the SDSCA and diabetes self-efficacy scales that are linked to the improvement in glycemic control in adults with Type 2 diabetes (Ibrahim et al., 2025; Romadlon et al., 2024). Structured logs will be used to monitor process measures, e.g., smart insulin pen onboarding completion, nurse-led dose reviews, compliance adherence, and documentation compliance by weekly audits of the standardized smart pen EHR template. The satisfaction of the patient and perceived usefulness of the smart insulin pen toolkit will be assessed using a short, validated survey at the end of the program, which will give information about the feasibility, engagement, and acceptability of the intervention.

Evaluation Criteria to Ensure the Planned Change Occurred

Clinical and process thresholds will also be used as a measure of success in the project. The most important clinical success measure is statistically and clinically significant mean fasting glucose baseline to 12 weeks; a target group mean under 130 mg/dL will be considered as a success in the context of effect size and confidence intervals, besides p-values. The secondary success criteria are as follows: 70% of all enrolled patients have completed smart insulin pen onboarding and monitoring protocols, [?]80% of all enrolled patients have adhered to weekly dosing review and missed dose follow-up by nursing staff, and documentation compliance [?]80% as measured by weekly audits of the standardized smart pen EHR template. Increasing baseline to 12 weeks, it would also be expected that measurable changes in mean SDSCA scores of insulin adherence and diabetes self-efficacy do occur.

It can be expected that patient satisfaction will reflect mean scores that are in the upper tertile of the survey scale, which implies that there will be acceptance of the smart insulin pen toolkit. Having clear clinical and process benchmarks, including fasting glucose reduction, better adherence scores, and higher self-management scores, is reasonable in line with evidence that shows that structured and technology-based insulin treatments with a set goal result in measurable changes in glycemic control and self-management (Galindo et al., 2021; Danne et al., 2024; Pantanetti et al., 2025; Chico et al., 2025). In terms of sustainability, a decrease in the EDs or urgent referrals due to diabetes visits compared with the 12-week baseline period will be reported, which are however, exploratory in the short implementation period.

Measurement Tools and Psychometric Properties

The important measurement tools are: (1) point-of-care fasting blood glucose and HbA1c (clinical laboratory measures that are supported by ADA standards), (2) self-management behaviors measured by the summary of diabetes self-care activities (SDSCA), (3) a validated diabetes self-efficacy scale, and (4) a brief patient satisfaction tool that has been validated in outpatient education settings. SDSCA is a popular instrument in diabetes QI and research and has proven to have reasonable reliability and construct validity in various outpatient groups (Ibrahim et al., 2025; Ricci et al., 2023).

Self-efficacy scales of diabetes that have been applied in equivalent studies have demonstrated high internal consistency (Cronbach alpha values are usually within the acceptable to good range) and responsiveness to change following education interventions (Chowdhury et al., 2024; Ibrahim et al., 2025). The clinical glucose measures are routine, and both fasting plasma glucose and HbA1c have proven a validity and reliability of tracking the glycemic control (ADA, 2023). In case any of the instruments chosen to be surveyed are proprietary or not available freely, the project leader would seek authorization from the instrument owners and would record it before they are used. The final report will mention instruments and the psychometric properties, and refer to this in the evidence matrix, in justifying the choice of instruments.

Data Analysis Plan

Data cleaning and descriptive statistics will be used to start the analysis by defining the sample (means, standard deviations, medians, interquartile range of continuous data; counts and percentages of categorical data). The main statistical analysis technique on the clinical outcome (fasting glucose) will involve the comparison of the baseline and 12-week mean values by using paired statistical tests: the paired t-test in case the differences are approximately normally distributed and the Wilcoxon signed-rank test in case normality is not satisfied.

The project will present the means difference, standard deviation, 95 percent confidence interval, p-value, and the effect size (Cohen’s d, where some parametric tests will be used or a suitable nonparametric effect size otherwise). In the case of insulin adherence and self-efficacy measures, pre-post paired comparisons are planned in the same way, where dose-logging data of smart insulin pens and validated self-efficacy measures will be applied. In the case of process measures (onboarding completion, dose review, missed-dose follow-up, documentation compliance), simple proportions will be analyzed and presented in the form of percentages with 95% confidence intervals. Visualization of changes over time and special-cause variation during implementation will be represented using trend and run-chart techniques that are typical of the methods of quality improvement (e.g., weekly run charts and control-chart annotations).

A descriptive and paired statistical analysis, supported by process monitoring tools like run charts, is consistent with the best practices of quality improvement research, and it has been demonstrated to be an accurate reflection of clinical and operational outcomes in technology-enabled insulin interventions (Knight et al., 2022). Different subgroup analyses (e.g., stratified by baseline glucose level, missed-dose frequency, or adherence to smart pen review workflows) will be performed based on t-tests or Mann-Whitney comparisons to investigate varying effects (assuming sufficient volume and quality of the data). Due to the projected sample size (at least 30-50 participants), it is anticipated that a more focused approach will be made on the estimation of effects, confidence, and practical significance as opposed to null-hypothesis significance testing.

Handling Missing Data, Statistical Assumptions, and Practical Considerations

The problem of missing data will be minimized by active scheduling, reminders, and versatile follow-up (phone, in-person). Missing data will be reported in the project, and the primary analyses will be done using available-case analysis; simple sensitivity analyses (such as last observation carried forward or multiple imputation) can be conducted in case of the nontriviality of missing data and when the assumption is satisfied. Visual and statistical tests will evaluate the normality assumption; nonparametric tests will be applied in case the assumption is violated.

Statistical significance will be interpreted as clinically relevant, and effect sizes will be used to make practical conclusions in the clinic. The use of proactive follow-up options and proper statistical management of no-show follow-ups is also evidenced as a tool to sustain data integrity and guarantee the credibility of the interpretation of intervention outcomes in clinical quality improvement studies (Romadlon et al., 2024; Ibrahim et al., 2025). All data will be analysed with the help of the typical statistical software that can be accessed within the academic/practicum environment (e.g., SPSS, R, or any other of that sort), and an analysis log will be kept to ensure the reproducibility of the analysis.

Data Management, Confidentiality, and Ethical Considerations

All information obtained in the EHR and survey tools will be de-identified and stored in password-unlocked, encrypted drives in alignment with HIPAA and the school’s instructions. It has also been shown that the high compliance with data encryption measures, secure storage, and the practice of de-identification would greatly lessen the chances of unauthorized access and remain compliant with the HIPAA privacy rules (Ricci et al., 2023). Identifiable linkage files as required to schedule or otherwise follow up will only be accessible to approved project team members; these files will be stored independently and destroyed at project close in accordance with institutional policy.

The minimum required identifiers will be asked in the data collection forms and the EHR Intervention template, and the investigations will be analyzed by using the study IDs. The learner will also make sure that he adheres to CITI training and any site-specific human subjects or QI governance procedures; where needed, the project lead will request an IRB determination or exemption as per institutional needs. Findings will be presented in an aggregate form to maintain confidentiality and sent to the stakeholders in monthly review meetings and a final project report.

Conceptual Model

Overview

Plan-do-study-act (PDSA) model is one of the fundamental quality improvement models that enable teams to experiment with changes in practice by using fast, cyclic models in a real-life clinical environment. The first stage of the model is the plan stage, during which the aim of the improvement is established, predictions are made, and data collection approaches are identified. When the do stage comes, the intervention is used on a small scale. The study stage is associated with analysing the collected data and comparing the results with those that have been predicted during the planning stage. Lastly, the act phase establishes the adoption, adaptation, or abandonment of the intervention on the results (Bechtold & Kome, 2025). The model is a cycle that allows refining it continuously and responding promptly to any barriers, workflow issues, or unforeseen consequences. The PDSA cycle is extensively known to be flexible, practical, and capable of facilitating evidence-based incremental changes in healthcare delivery.

PDSA Model Incorporated Into the Project

All the stages of the implementation of the intervention of the smart insulin pen clinical management toolkit will be organized with the PDSA framework. During the Plan stage, the project team will complete workflow modifications, set targets on outcomes (such as mean fasting glucose <130 mg/dL and increased insulin adherence), develop patient onboarding resources about smart insulin pens, and educate personnel on how to use the device, review dose logs, missed doses, and standardized procedures of EHR documentation. In the Do phase, the toolkit will be launched, where eligible patients will be identified with reports of EHR data, and the nursing staff will provide a standardized smart pen onboarding, observe dose-logging data, react to missed-dose alerts, and record all encounters through a structured EHR template.

At the Study phase, the levels of fasting glucose, HbA1c when available, insulin compliance, missed dose frequency, and documentation compliance will be assessed every two weeks to determine whether the initial trends indicate improvement. The project lead and preceptor will study deviations, obstacles, or workflow inefficiencies and compare results with baseline figures. It has been demonstrated that the PDSA cycle can improve the level of intervention fidelity and increase the speed of quality improvement by helping teams to test changes in small and iterative steps and changing processes using real-time performance data (Turner et al., 2022). Lastly, during the Act stage, the required adjustments, e.g., scheduling changes, dose audit exercises, support documentation, or follow-up care plans of patients, will be presented before the commencement of the next cycle. The iterative strategy will provide the smart insulin pen intervention with gradual effectiveness, patient-centeredness, and clinic-specificity.

Connection of the PDSA Model to the Project Goals and PICOT Question

The PICOT question that is presented in the project centers on whether fasting blood glucose and insulin adherence can be reduced in 12 weeks through implementation of an ADA-adjusted clinical management toolkit of the use of smart insulin pen in adult patients with uncontrolled Type 2 diabetes. The PDSA model aligns well with the objective because it offers the mechanism of implementing and optimizing the smart insulin pen intervention process in a systematic and methodical way. Cycles of the model enable the team to evaluate PICOT-consistent outcomes, such as fasting glucose, HbA1c, where available, rate of missed doses, compliance with dose review systems, make progress in glycemic improvement, and modify workflows to promote clinical value.

Since the PICOT question focuses on improvement of glycemic control and adherence to insulin use over a specific time, continuous measurement and feedback inherent in the PDSA approach warrant the need to maintain a similarity between the intervention and the intended results. The project objective of enhancing the adherence of the staff to standardized smart pen workflows is also supported by the model, as the continuous monitoring, dose review, and real-time evaluation are embedded in the implementation strategy (Bechtold and Kome, 2025). A combination of the PICOT framework and the PDSA approach turns out to be a highly integrated framework that facilitates credible practice changes as well as brings about quantifiable and sustained improvements to insulin management, patient engagement, and glycemic outcomes.

How the Model Will Guide the Project

The PDSA model will be used to direct the project as it will influence the decision-making process of implementation, the data interpretation process, and the introduction of refinements. The model offers a systematic approach to pilot changes (including changing smart insulin pen dose review procedures, changing missed-dose follow-up processes, or enriching documentation processes) before they can be adopted by the whole population, and minimize risk and enhance sustainability. The plan phase guarantees understanding of the roles of the team, anticipated results, and measures of data, such as fasting glucose, HbA1c, where applicable, insulin compliance, and frequency of missed doses. The do stage will provide a gradual sustainability of the implementation of the smart insulin pen intervention by the professionally trained nursing personnel. Throughout the research period, the process and clinical data review will aid in detecting gaps, working inefficiencies, or unforeseen effects.

The act phase will facilitate the introduction of improvements, which will strengthen a culture of continuous learning and compliance with standardized smart pen protocols. The hierarchical but adaptable leadership is a necessity in primary care environments where unpredictability in the workflow and patient complexity may influence the quality improvement outcomes (Danne et al., 2024). With the foundation of the intervention in a cyclical, evidence-based model, the project will be in a position to attain lasting changes in nurse-managed insulin processes, patient interaction, and glycemic results in a fluid primary care setting.

Literature Supporting PDSA Use in Similar Projects

The PDSA model has been extensively recorded in the chronic disease management and diabetes care improvement endeavors. It has been shown that the interventions implemented with the help of PDSA-guided smart insulin pens result in substantial glycemic control, improvement of insulin adherence, and clinical workflow efficiency (Jackson et al., 2023). As one instance, Pullyblank et al. (2024) showed that PDSA cycles were associated with enhanced patient self-efficacy in managing insulin and increased adherence to smart pen monitoring protocols among staff. The model has also been applied to refine EHR templates, improve accuracy in recording dose logs, follow up on missed doses, and standardize chronic disease-based care processes in outpatient settings (Carr et al., 2023). The results justify the choice of PDSA as the most suitable model to be used in the iterative testing, workflow alignment, and continuous evaluation directions within the project of the smart insulin pen clinical management toolkit.

Methodology, Budget, and Ethical Considerations

Project Assumptions and Methodological Approach

This project is based on the quality improvement (QI) design, which focuses on the systematic implementation, continuous evaluation, and further quality improvement of the smart insulin pen clinical management toolkit intervention. The essence of the assumption made by the project is that, when implemented in structured clinical processes, standardized and nurse-led smart insulin pens with dose logs and missed-dose alerts will result in improved fasting glucose, increased insulin adherence, and stricter glycemic control. The hypothesis is supported by the current evidence that proves the significance of technology enable insulin management in a primary care environment.

It has been found that adult patients who utilize smart insulin pens with the help of a structured nursing supervision demonstrate a major improvement in the glycemic outcomes, dose adherence, and involvement in self-management behaviors in comparison to patients who receive the usual insulin delivery (Galindo et al., 2021; Danne et al., 2024; Pantanetti et al., 2025). The other assumption is that staff will be exposed to obligatory training, take up conventional dose review and documentation protocols, and remain faithful to the toolkit workflows. The pre-post QI project design that depends on the PDSA identifies the use of a pre-post research design, which enables the smart insulin pen intervention to be tested, assessed, and revised throughout its process by organized iterative cycles.

Human Subjects Protection

Even though the initiative is not human subjects research, but is a QI project, it is necessary to consider ethical considerations. The involvement in the intervention of the smart insulin pen clinical management toolkit is regarded as part of the regular clinical work, and there is no experimental process involved. Nevertheless, patient data gathered to assess the outcomes, such as fasting glucose and HbA1c, dose-logging, and missed dose alerts, will be de-identified before any analysis is conducted to guarantee patient privacy. Only authorized nursing personnel and clinicians working directly with patients onboarding, dose review, and documentation will have access to identifiable patient data. IRB/QI oversight of the project will be maintained, and ethical conduct expected of the learner will be in line with the expectations of the institution in regard to CITI training and HIPAA standards.

Project Limitations and Mitigation Strategies

The implementation and results of the project can be influenced by a number of limitations. The variability in the staff workload can be considered one of the limitations, as it can lead to decreased availability to provide the regular smart insulin pen onboarding, dose review, and documentation. To curb the issue, smart pen workflows will be incorporated into the current appointment schedules, and the project lead will liaise with the preceptor so that the staff will be supported in the busiest clinic hours. The second weakness is the possibility of poor patient engagement, especially when the patient has transportation, employment, or socioeconomic barriers. The follow-up on dose will be done via reminder calls, flexible scheduling, and short telephone/portal-based follow-up to minimize missed monitoring and review meetings.

It has been demonstrated that the introduction of flexible schedules, notifications, and follow-up, which can be conducted remotely, can play a vital role in engaging patients and increasing their insulin adherence, especially in the context of socioeconomic or logistical resistance (Ricci et al., 2023). The third limitation is that the project is of a short time with the possibility that it does not enable the assessment of the glycemic stability or sustained adherence. In this regard, the data regarding fasting glucose and smart pen adherence will be monitored monthly, and the early trend data will be prioritized to interpret. The accuracy of data and variability of documentation are also risks.

The solution to these challenges will be to provide the staff with organized training on smart pen workflows and carry out weekly audits of dose documentation, missed-dose alerts, and EHR documentation to verify that standardized fields are accurately and consistently filled. Lastly, limited generalizability can be caused by the small sample sizes of samples (typically used in QI projects). Nonetheless, descriptive statistics, process measurements, and compliance monitoring will still enable meaningful assessment of the trends and practical influence on the insulin control and glycemic outcomes.

Project Budget and Resource Allocation

Whereas the plan is a low-cost QI project, there are several costs and resource considerations inherent to implementation. The primary budget items will consist of personnel effort in training to use the smart insulin pen clinical management toolkit, project meetings, documentation review, and patient onboarding and dose review. The amount of time that will be required to train will be about 2-3 hours per staff member, and it can easily be included in the current professional development time. The identification of patients, making sessions, and following up on missed doses, as well as taking part in monthly project huddles, will require additional staff time. Neither significant material resources are needed, and the resources will include printed toolkit instructions, SMART goal workbook, dose record, and attendance sheet.

The expenses should fall within the normal patient education and technology-support budget of the clinic. Several changes in EHR could be made to incorporate standardized smart pen documentation fields that could take the IT personnel about 1-2 hours. Internal IT labor must be pre-budgeted, but the effort must be reflected as being part of the project budget. The learner will not need any external funding, but the time spent by the project lead, such as coordinating and monitoring the staff and analyzing the data, will be a non-financial cost to the organization. The acknowledgement of the staff time and IT support as a budget item facilitates transparency and proper planning of the organization in the long-term sustainability of the smart insulin pen intervention.

HIPAA Compliance and Data Security Plan

The project will ensure that there are strict measures regarding patient confidentiality and data security. Patient names, date of birth, and medical record numbers are all identifiable data that will not be exported to be analyzed and will be stored in the safe EHR. The project data spreadsheet will only record the de-identified information (i.e., fasting glucose values, attendance, self-management scores). The spreadsheet will be kept on a password-protected, encrypted organization-issued laptop, and the learner and preceptor have access to the spreadsheet. No information will be stored in personal computers or any other cloud-based storage that is not part of the secure system of the organization. Physical materials (e.g., sign-in sheets, printed education logs, etc.) will be kept in locked cabinets on the clinical site and shredded once all data is entered.

Role-based access will be used to prevent unauthorized users from accessing the EHR, and staff will leave the system after each use with the aim of eliminating unauthorized access. By following the principles of data security and confidentiality, such as de-identification, data encryption, limited access, etc., one complies with the HIPAA norms and demonstrates that this approach can reduce the risk of data breaches and preserve the privacy of patients in the context of clinical quality improvement (Ibrahim et al., 2024). Any data transmission will be made via secure and HIPAA-compliant channels that will have the approval of the organization. The measures identified guarantee complete adherence to HIPAA standards and are in line with optimal practices in health information protection in the course of QI initiatives.

Conclusion

The proposed project describes a systematic, evidence-based intervention that would lead to better diabetes self-management and glycemic control with the introduction of an ADA-compliant Smart Insulin Pen Clinical Management Toolkit. The QI plan incorporates a well-outlined implementation plan, a stringent data collection and evaluation model, and the utilization of the PDSA model to facilitate repetitive enhancement of the project over the 8-10 week project term. Engaging interprofessional team members, internal and external stakeholders, and having a good working relationship with the preceptor will guarantee organizational alignment, involvement of the staff, and patient-centered care. The research approach focuses on ethical concerns, patient confidentiality, HIPAA regulation, and a realistic budget to facilitate the feasibility of operations.

The work plan is written on a weekly basis, which shows that the execution is ready, and the toolkit approach directed to the organization of the work every week reinforces the nursing practice by standardizing the process of insulin dose review, adherence monitoring, and clinical follow-up. The proposal offers a logical and practical outline regarding the achievement of quantifiable changes in self-management of insulin, changes in fasting glucose, and more active patient interaction, as well as support of the advanced nursing leadership and quality improvement competencies.

Related Assessment for this class: NURS FPX 9010 Assessment 1